| [1] |
Shi Y, Wang W, Qiu W, et al. Learning curve from 450 cases of robot-assisted pancreaticoduocectomy in a high-volume pancreatic center: optimization of operative procedure and a retrospective study[J]. Ann Surg, 2021, 274(6):e1277-e1283.
doi: 10.1097/SLA.0000000000003664
URL
|
| [2] |
Shi Y, Jin J, Qiu W, et al. Short-term outcomes after robot-assisted vs. open pancreaticoduodenectomy after the learning curve[J]. JAMA Surg, 2020, 155(5):389-394.
doi: 10.1001/jamasurg.2020.0021
URL
|
| [3] |
Weng Y, Jiang Y, Fu N, et al. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis[J]. Surg Endosc, 2021, 35(7):3437-3448.
doi: 10.1007/s00464-020-07791-2
URL
|
| [4] |
Deveson IW, Gong B, Lai K, et al. Evaluating the analy-tical validity of circulating tumor DNA sequencing assays for precision oncology[J]. Nat Biotechnol, 2021, 39(9):1115-1128.
doi: 10.1038/s41587-021-00857-z
pmid: 33846644
|
| [5] |
Akce M, Zaidi MY, Waller EK, et al. The potential of CAR T cell therapy in pancreatic cancer[J]. Front Immunol, 2018, 9:2166.
doi: 10.3389/fimmu.2018.02166
pmid: 30319627
|
| [6] |
Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J]. Mol Ther, 2010, 18(4):843-851.
doi: 10.1038/mt.2010.24
pmid: 20179677
|
| [7] |
Thistlethwaite FC, Gilham DE, Guest RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity[J]. Cancer Immunol Immunother, 2017, 66(11):1425-1436.
doi: 10.1007/s00262-017-2034-7
pmid: 28660319
|
| [8] |
Nagarsheth NB, Norberg SM, Sinkoe AL, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers[J]. Nat Med, 2021, 27(3):419-425.
doi: 10.1038/s41591-020-01225-1
pmid: 33558725
|
)
